Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
20 Results for "
SIRT-IN-1
" in MedChemExpress (MCE) Product Catalog:
Products (20)
20 Results for "SIRT-IN-1" in MCE Product Catalog:
1
1 Cited Publications
Cat. No.: HY-16615
CAS No.: 1431411-60-7
Target:
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
SIRT-IN-1 is a potent inhibitor of SIRT1/2/3, with IC50s of 15, 10, 33 nM, respectively.
63
63 Publications Verification
Research Areas:
SRT 1720 dihydrochloride is a selective and orally active activator of SIRT1 with an EC50 of 0.10 μM, and shows less potent activities on SIRT2 and SIRT3 .
63
63 Publications Verification
Research Areas:
SRT 1720 monohydrochloride is a selective and orally active activator of SIRT1 with an EC50 of 0.10 μM, and shows less potent activities on SIRT2 and SIRT3 .
1
1 Cited Publications
PROTAC Sirt2 Degrader-1 is a SirReal-based PROTAC, acts as a Sirt2 degrader, composed of a highly potent and isotype-selective Sirt2 inhibitor, a linker, and a bona fide Cereblon ligand for E3 ubiquitin ligase. PROTAC Sirt2 Degrader-1 shows an IC50 of 0.25 μM for Sirt2, with no effect on Sirt1/Sirt3 (IC50s>100 μM) [1].
Synonyms: 4′‐BR
Target:
Research Areas:
4'-Bromo-resveratrol (4′‐BR) is a dual SIRT1/SIRT3 inhibitor with an IC50 of 0.2 mM for both targets. 4'-Bromo-resveratrol induces caspase-dependent apoptosis, induces G0/G1 cell cycle arrest, and inhiibits proliferation. 4'-Bromo-resveratrol reduces lactate production, glucose uptake, and NAD +/NADH ratio, and downregulates lactate dehydrogenase A and glucose transporter 1 (GLUT1). 4'-Bromo-resveratrol can be used for the research of melanoma [1].
Cat. No.: HY-16616
CAS No.: 1431411-66-3
Target:
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
SIRT-IN-2 is a potent inhibitor of SIRT1/2/3, with IC50s of 4, 4, 7 nM, respectively.
Cat. No.: HY-162837
Target:
Research Areas:
AURKA against 1 is an inhibitor of AURKA (IC50 less than 0.5 nM), targeting endogenous lysine (K162) acetylation, and has anti-proliferation activity against tumor cells. AURKA against 1 induces K162 acetylation, and the kinase activity of AURKA is reversibly restored in HCT116 cells transfected with SIRT3 .
Cat. No.: HY-155727
CAS No.: 670267-73-9
Sirt1/2-IN-2 (compound hsa55) is a dual inhibitor of SIRT1/2 with IC50s of 1.8 μM (SIRT1) and 2.4 μM (SIRT2), respsectivley. Sirt1/2-IN-2 completely blocks p53 deacetylation, and increase of p53 and α-tubulin acetylation. Sirt1/2-IN-2 induces apoptosis and shows anti-proliferation activity against human leukemia cell lines [1].
Cat. No.: HY-16605
CAS No.: 23491-48-7
Research Areas:
SIRT6-IN-6 (compound 6d) is a potent and selective SIRT6 inhibitor with an IC50 of 4.93 μM and a Ki of ~10 μM. SIRT6-IN-6 shows selectivity against other members of the HDAC family (SIRT1-3 and HDAC1-11). SIRT6-IN-6 significantly increases the level of glucose transporter GLUT-1, thereby reducing blood glucose in a mouse model of type 2 diabetes. SIRT6-IN-6 can be used for type 2 diabetes research [1].
Cat. No.: HY-107453
CAS No.: 1862237-99-7
Synonyms: PROTAC SIRT2-bINdINg moiety 1
Research Areas:
SirReal1-O-propargyl is a selective and highly potent Sirtuin 2 (Sirt2) inhibitor, with an IC50 of 2.4 μM. SirReal1-O-propargyl, the SirReal1-based moiety, binds to the cereblon ligand via a linker to form PROTAC to degrade Sirt2 . SirReal1-O-propargyl is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Cat. No.: HY-155729
CAS No.: 2999646-13-6
Sirt1/2-IN-4 (compound PS3) is a triple inhibitor of SIRT1/2/3 with IC50s of 1.2 μM (SIRT1), 1.9 μM (SIRT2), and 18.6 μM (SIRT3), respsectivley. Sirt1/2-IN-4 completely blocks p53 deacetylation, with potential anti-cancer activity [1].
Cat. No.: HY-W109401
CAS No.: 1431411-18-5
Target:
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
SIRT-IN-6 (Compound 14) is a pan-inhibitor of SIRT1/2/3 with IC50 values of >50 μM. SIRT-IN-6 is promising for research of metabolic, inflammatory, oncologic and neurodegenerative disorders [1].
Cat. No.: HY-168172
Target:
Research Areas:
LDH-IN-3 (compound E38) is an inhibitor of LDH, promising protective agent for ischemic nerve damage in the eye and brain. LDH-IN-3 acts its function via HO-1/SIRT1 pathway. [1].
Cat. No.: HY-15145R
CAS No.: 2060259-60-9
Research Areas:
SRT 1720 (monohydrochloride) (Standard) is the analytical standard of SRT 1720 (monohydrochloride). This product is intended for research and analytical applications. SRT 1720 monohydrochloride is a selective and orally active activator of SIRT1 with an EC50 of 0.10 μM, and shows less potent activities on SIRT2 and SIRT3 .
Cat. No.: HY-155784
CAS No.: 2170274-53-8
Research Areas:
SPC-180002 is a SIRT1/3 dual inhibitor, with IC50 values of 1.13 and 5.41 μM, respectively. SPC-180002 disturbs redox homeostasis via ROS generation, which leads to an increase in both p21 protein stability and mitochondrial dysfunction. SPC-180002 strongly inhibits cell cycle progression and cancer cell growth. SPC-180002 activates the Nrf2 signaling pathway [1].
Cat. No.: HY-155728
CAS No.: 301313-42-8
Sirt1/2-IN-3 (compound PS9) is a dual inhibitor of SIRT1/2 with IC50s of 1.4 μM (SIRT1) and 2.0 μM (SIRT2), respsectivley. Sirt1/2-IN-3 completely blocks p53 deacetylation, and increase of p53 and α-tubulin acetylation. Sirt1/2-IN-3 induces apoptosis and shows anti-proliferation activity against human leukemia cell lines [1].
Cat. No.: HY-153509
CAS No.: 1392810-44-4
Sirtuin-IN-1 (Compound 18) is a SIRT1/2 inhibitor (IC50s: 6.2 μM and 4.2μM for SIRT1 and SIRT2, respectively). Sirtuin-IN-1 induces G1 cell cycle arrest. Sirtuin-IN-1 exhibits potent anti-cancer activity against glioma [1].
Cat. No.: HY-136713
CAS No.: 143034-06-4
Target:
Research Areas:
Sirt1/2-IN-5 is a SIRT1/SIRT2 inhibitor with human SIRT1 IC50 0.3 μM and human SIRT2 IC50 values 1.2 μM and pIC50 5.82. Sirt1/2-IN-5 inhibits NAD +-dependent deacetylase activity of SIRT1 and SIRT2. Sirt1/2-IN-5 can be used for the research of cancer, neurodegenerative disease [1] .
Cat. No.: HY-103636R
CAS No.: 2098487-75-1
Target:
Research Areas:
PROTAC Sirt2 Degrader-1 (Standard) is the analytical standard of PROTAC Sirt2 Degrader-1 (HY-103636). This product is intended for research and analytical applications. PROTAC Sirt2 Degrader-1 is a SirReal-based PROTAC, acts as a Sirt2 degrader, composed of a highly potent and isotype-selective Sirt2 inhibitor, a linker, and a bona fide Cereblon ligand for E3 ubiquitin ligase. PROTAC Sirt2 Degrader-1 shows an IC50 of 0.25 μM for Sirt2, with no effect on Sirt1/Sirt3 (IC50s>100 μM) [1].
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
